A Methodical Review on Omicron -a New Variant as a Drug Developer

In mid-November 2021, the new OMICRON variety was first discovered in South Africa. As of today, the OMICRON version already appeared on December 15, 2021. Around 77 countries are affected, with the bulk of cases originating in the United States, India, the United Kingdom, and South Africa. OMICRON-positive instances were also reported. The first mortality associated with the novel COVID-19 mutation was reported in the United Kingdom. Recently, a sister variant of OMICRON, 21L or BA.2, has also been discovered. Due to its enormously high number of mutations, viewed enhancement in immune evasion and transmissibility, OMICRON was developed as a new variant of concern (VOC) by the WHO on 26 November 2021. On a global pandemic scale, positive selection of SARSCoV-2 mutations appears to have begun in late 2020. Since then, the virus has been evolving on two fronts: immune evasion and enhanced transmissibility, as expressed by Delta. This review elaborates the effects of drugs in the management of OMICRON.Copyright © 2023 Society of Pharmaceutical Sciences and Research. All rights reserved.

Reimposing of marketed drugs in treatment of COVID 19 by insilicomethods

Objective: Galidesivir-BCX4430 is an antiviral broad spectrum drug with an adenosine nucleotide analogue. Galidesivir behaves in vitro against numerous RNA viral pathogens, which include the filoviruses and develops irresistible contagious to humans, for example, MERS CoV and SARS-CoV. In vivo, BCX4430 is agile after intramuscular, intraperitoneal administration, and on more, oral organization in an assortment of test contaminations. Recent studies have stated that this drug is currently being examined for treatment of COVID 19 as previously it has been used in zika virus, Ebola and also Hepatitis C. Methods: The study was to investigate the binding efficiency of selected currently COVID 19 treating drugs and visualized by Discovery Studio 4.1 Visualizer. The target sites of drugs selected for the study were extracted from Protein Data Bank, and the ligands selected for the study are (R1-R7)Among the compounds treated with targets are screened in Autodock. CompoundR5 shows greater binding efficacy Results: Compound R5 shows better antiviral activity and inhibition and active protease inhibitor and promotes to treat Sars cov.2 (COVID-19). © 2020, Advanced Scientific Research. All rights reserved.